arrow
I

Iphigénie Korakis

unicancer
H指数:9
被引数:300

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

肿瘤局部CD40激动与MP0317,一种FAP x CD40 DARPin,重新编程晚期实体瘤患者的肿瘤微环境: 一项开放标签,非随机,剂量递增的1期研究

2026-05-010
OAAI
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti- PD-1 monoclonal antibody in patients with advanced solid tumours

I期剂量递增研究评估OSE-279(一种抗PD-1单克隆抗体)在晚期实体瘤患者中的安全性、药代动力学和药效动力学

2026-04-090
PRE
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum

加速癌症治疗优化:癌症药物论坛的多利益相关方路线图

2026-01-010
OAAI
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis

瑞戈非尼联合阿维鲁单抗在晚期胃肠胰神经内分泌肿瘤中的应用:一项II期试验及相关分析

2025-04-090
PRE
Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors

CFT1946的I期研究初步结果,CFT1946是一种新型BIDAC降解剂,用于突变型BRAF V600实体瘤。

2024-09-012
PRE
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study

Lenvatinib联合pembrolizumab治疗先前治疗的晚期三阴性乳腺癌患者: 来自LEAP-005 2期研究的三阴性乳腺癌队列的结果

CANCER
IF5.1
2024-06-211
OAAI
A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab
2024-06-010
PRE
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
2024-01-2410
PRE
Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors
2023-04-042
PRE
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

Cabozantine-nivolumab序列在转移性肾细胞癌中的应用: CABIR研究

2022-06-067
OA
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
2022-02-0133
PRE
Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
2021-09-018
OAAI
Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study
2021-09-010
OAAI